Aktis Oncology, Inc. (NASDAQ:AKTS) is a clinical-stage oncology company that has recently made headlines with its initial public offering (IPO). The company focuses on developing innovative cancer treatments, aiming to make a significant impact in the biotech sector. Aktis competes with other biotech firms in the oncology space, striving to bring new therapies to market.
Aktis Oncology's IPO involved offering 17.65 million shares at $18 each. The IPO, which took place on January 12, 2026, was upsized, and the underwriters exercised their option to purchase an additional 2.65 million shares at the same price. This move is expected to bring the total gross proceeds to approximately $365.4 million, as highlighted by GlobeNewswire. The company's shares began trading on the Nasdaq Global Select Market under the ticker symbol "AKTS" on January 9, 2026.
Aktis Oncology's IPO is the first sizable offering of 2026, marking a significant milestone in the U.S. IPO market. This event underscores the company's growth potential and strategic positioning within the biotech industry, as noted by Seeking Alpha. Currently, AKTS is trading at $20.56, reflecting a slight decrease of 1.20% or $0.25. The stock has experienced fluctuations, with a daily low of $19.69 and a high of $21.43. Over the past year, AKTS has seen a high of $29.16 and a low of $19.02. The company's market capitalization stands at approximately $1.08 billion, with a trading volume of 234,338 shares on the NASDAQ exchange.
